Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.57 |
| ▸ | PPARD | Q03181 | 1/20 | 0.57 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.57 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7461114 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL27456709 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL5972273 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2718891 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL1027845 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL8469082 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2702837 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL17480708 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL5972279 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL3625304 | 1.00 | GPR84 (0.59) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009101412-A1 | TOPICAL PHARMACEUTICAL COMPOSITION | CIPLA LIMITED (IN) | 2009-08-20 | — | — | WO | claimed |
| CN-122028939-A | Thyroid hormone delivery system comprising lipid or polymer nanoparticles | 里卡尔多·泰尔齐与西尔维奥·阿尔比尼基金会 | 2026-05-12 | — | — | CN | disclosed |
| CN-119072463-A | Novel ionizable cationic lipids | 维硕公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-114929205-B | Lipid nanoparticle compositions comprising end-capped DNA and cleavable lipids and methods of use thereof | 世代生物公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-116437964-A | Methods for encapsulating polynucleotides into reduced size lipid nanoparticles and novel formulations thereof | 世代生物公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116171150-A | Method for lyophilizing lipid nanoparticles | 阿克丘勒斯治疗公司 | 2023-05-26 | — | — | CN | disclosed |
| CN-115697321-A | Cationic lipids for lipid nanoparticles for delivering therapeutic agents to hepatic stellate cells | 盖纳万科学有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115516090-A | TREM compositions and uses thereof | 旗舰先锋创新VI有限责任公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-115397984-A | Recombinase compositions and methods of use | 旗舰先锋创新VI有限责任公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115003312-A | High density lipoprotein-like nanoparticles as inducers of iron death in cancer | 西北大学 | 2022-09-02 | — | — | CN | disclosed |
| US-6733777-B2 | CYTOFECTINS; SUPPLYING EXOGENOUS COMPOUNDS INTO CELLS | QIAGEN GMBH (DE) | 2004-05-11 | — | — | US | disclosed |
| US-20040077582-A1 | Cationic reagents for transfection | ERBACHER CHRISTOPH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20030229013-A1 | Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2003-12-11 | — | — | US | disclosed |
| US-20030229017-A1 | Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY | 2003-12-11 | — | — | US | disclosed |
| EP-1319667-A2 | Solid phase method for the synthesis of peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2003-06-18 | — | — | EP | disclosed |
| US-6458381-B1 | COMPLEXING LYSINE-BIS-(O,O*-9-OCTADECENOYL-B-HYDROXYETHYL) AMIDE WITH LIPID, RNA, DNA, OR POLYPEPTIDE | Sourovoi, Andrej (RU) | 2002-10-01 | — | — | US | disclosed |
| US-20010048939-A1 | Cytofectins; supplying exogenous compounds into cells | QIAGEN GMBH (DE) | 2001-12-06 | — | — | US | disclosed |
| EP-1003556-A2 | CATIONIC REAGENTS FOR TRANSFECTION | QIAGEN GmbH (DE) | 2000-05-31 | — | — | EP | disclosed |
| WO-1998019709-A2 | CATIONIC REAGENTS FOR TRANSFECTION | QIAGEN GMBH (DE) | 1998-05-14 | — | — | WO | disclosed |
| EP-0143881-A2 | Process for the preparation of an alkyl ester of L-alpha-aspartyl-L-phenyl-alanine | GEMA S.A. (ES) | 1985-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229013-A1 | Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same | DLST, LNPEP, LSS | GPR84 1551/4885FFAR1 1324/4885MAPT 4301/4885 |
| US-20030229017-A1 | Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same | DLST, LNPEP, LSS | GPR84 1551/4885FFAR1 1324/4885MAPT 4301/4885 |
| US-20010048939-A1 | Cytofectins; supplying exogenous compounds into cells | PHOSPHO1, CYTH2, PCTP | GPR84 2312/4885FFAR1 1854/4885MAPT 4828/4885 |
| US-20040077582-A1 | Cationic reagents for transfection | PHOSPHO1, PCTP, CYTH2 | GPR84 2755/4885FFAR1 2933/4885MAPT 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.